Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells

British Journal of Pharmacology

Volumn 160, Issue 7, 2010, Pages 1690-1698

  Rose, A ^a   Grandoch, M ^a   Vom Dorp, F ^a   Rubben H ^a   Rosenkranz, A ^b   Fischer, J W ^a   Weber, A A ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

bladder cancer; ERK; sorafenib; urothelial cancer

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE INHIBITOR; RAS PROTEIN; SORAFENIB;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UROGENITAL TRACT CANCER; UROTHELIAL CARCINOMA;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIDINES; RAS PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 77954324477     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00838.x     Document Type: Article

References (27)

1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al. (2006). Phase II study of sorafenib in patients with advanced hepatocelluar carcinoma. J Clin Oncol 24:4293 4300.
2. Adjei AA (2001). Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062 1074.
3. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
4. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO (2008). Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 68:5236 5245.
5. Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S et al. (2009). Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 20:616 624.
6. Dhillon AS, Hagan S, Rath O, Kolch W (2007). MAP kinase signalling pathways in cancer. Oncogene 26:3279 3290.
7. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y et al. (2008). Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 68:6109 6117.
8. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR (2004). Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 10:4874 4884.
9. vom Dorp F, Börgermann C, Rose A, Becker M, Rübben H (2008). Targeted therapy for metastatic bladder cancer. Urologe 47:1311 1314.
10. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ et al. (2009). Phase 2 trial of sorafenib in patients with advanced urothelial cancer. A trial of the Eastern Cooperative Oncology Group. Cancer 115:4090 4095.
11. Fontana D, Bellina M, Scoffone C, Cagnazzi E, Cappia S, Cavallo F et al. (1996). Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol 29:470 476.
12. Gradinetti CA, Goldspiel BF (2007). Sorafenib and sunitinib: a novel targeted therapies for renal cell cancer. Pharmacotherapy 27:1125 1144.
13. Hermann A, Schrör K, Weber A-A (2002). CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells. Eur J Cell Biol 81:213 221.
14. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumour angiogenesis, and induces tumour cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851 11858.
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378 390.
16. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T et al. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602 4608.
17. Nicholson RI, Gee JM, Harper ME (2001). EGFR and cancer prognosis. Eur J Cancer 37 (Suppl. 4 S9 15.
18. Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y et al. (2009). Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs DOI: 10.1007/s10637-009-9321-x Epub ahead of print GK, Halabi S, Sanford BL, Bajorin D, Small EJ, Cancer and Leukaemia Group B (2008). A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. Br J Urol Int 101:20 25.
19. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J et al. (2007). Cell cycle dependent and schedule-dependent antitumour effects of sorafenib combined with radiation. Cancer Res 67:9443 9454.
20. Przybojewska B, Jagielo A, Jalmuzna P (2000). H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet Cytogenet 121:73 77.
21. Rosato RR, Almenara JA, Coe S, Grant S (2007). The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 67:9490 9500.
22. Vageli D, Kiaris H, Delakas D, Anezinis P, Cranidis A, Spandidos DA (1996). Transcriptional activation of H-ras, K-ras, and N-ras proto-oncogenes in human bladder tumors. Cancer Lett 107:241 247.
23. Wilhelm S, Chien DS (2002). BAY 43-9006: preclinical data. Curr Pharm Des 8:2255 2257.
24. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. (2004). Bay 43-9006 exhibits broad spectrum oral antitumour activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 64:7099 7109.
25. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalling. Mol Cancer Ther 7:3129 3140.
26. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S et al. (2006). Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175:1245 1252.
27. Zhang Z, Zhou X, Shen H, Wang D, Wang Y (2009). Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 7:41.